TY  - GEN
AU  - Gojo,Ivana
AU  - Tan,Ming
AU  - Fang,Hong-Bin
AU  - Sadowska,Mariola
AU  - Lapidus,Rena
AU  - Baer,Maria R
AU  - Carrier,France
AU  - Beumer,Jan H
AU  - Anyang,Bean N
AU  - Srivastava,Rakesh K
AU  - Espinoza-Delgado,Igor
AU  - Ross,Douglas D
TI  - Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia
SN  - 1557-3265
PY  - 2013///0927
KW  - ATP Binding Cassette Transporter, Subfamily B
KW  - genetics
KW  - ATP Binding Cassette Transporter, Subfamily G, Member 2
KW  - ATP-Binding Cassette Transporters
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacology
KW  - Cytarabine
KW  - administration & dosage
KW  - Etoposide
KW  - Female
KW  - Gene Expression Regulation, Leukemic
KW  - drug effects
KW  - Humans
KW  - Hydroxamic Acids
KW  - Karyotype
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Proteins
KW  - Recurrence
KW  - Translational Research, Biomedical
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor Decoy Receptors
KW  - Vorinostat
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.1158/1078-0432.CCR-12-3165
ER  -